(BSTG) to Host Pre-Clinical Research Update, Q1 Call

HOLLISTON, Mass., May 3, 2016  — Biostage, Inc. (NASDAQ: BSTG) a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will host a conference call to provide an update on their collaborative large animal pre-clinical research and to review its first quarter results on Thursday, May 12, 2016 at 9:00am ET. The research update and Q1 2016 results will be announced pre-market that day.  On the call, management may respond to questions from the audience on any of a number of topics related to the business, including preclinical research, operations, plans and outlook.

Participating in the call will be CEO, Jim McGorry, Chief Medical Officer, Saverio La Francesca, and CFO, Tom McNaughton.

Conference Call Information:

Date/Time:  Thursday, May 12^th at 9:00 am ET

Call Dial In #:  877-407-8293 U.S. or 201-689-8349 Int’l

Live Webcast/Replay:  biostage.com/events-and-presentations

Audio Replay #:  877-660-6853 U.S. or 201-612-7415 Int’l – Access ID #13636819

About Biostage, Inc.: www.biostage.com
Biostage is a biotechnology company developing bioengineered organ implants based on the company’s new Cellframe^TM technology which combines a proprietary biocompatible scaffold with a patient’s own stem cells to create Cellspan^TM organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

Cellspan implants are currently being advanced and tested in a collaborative preclinical study. This testing is intended to expand the base of preclinical data in support of Biostage’s goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016. The IND will seek approval to initiate clinical trials for its esophageal implants in humans.

Forward Looking Statements:
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing ourStonecold3 Cellframe technology,  which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Twitter: BiostageIR

StockTwits:  BiostageIR

Media/Investor Relations Contact:
Tom McNaughton	David Collins, Bill Jones
Chief Financial Officer	Catalyst Global LLC
774-233-7321	212-924-9800 w; 917 734-0339 m
	bstg@catalyst-ir.com